Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $425.2 million.

  • Ultragenyx Pharmaceutical's Cash & Current Investments fell 3158.9% to $425.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $425.2 million, marking a year-over-year decrease of 3158.9%. This contributed to the annual value of $610.0 million for FY2024, which is 568.53% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Cash & Current Investments stood at $425.2 million for Q3 2025, which was down 3158.9% from $487.6 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's Cash & Current Investments' 5-year high stood at $965.4 million during Q1 2021, with a 5-year trough of $412.1 million in Q1 2024.
  • Its 5-year average for Cash & Current Investments is $635.9 million, with a median of $610.0 million in 2024.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Cash & Current Investments skyrocketed by 4555.1% in 2021, and later tumbled by 5025.25% in 2023.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Cash & Current Investments stood at $740.2 million in 2021, then grew by 1.02% to $747.8 million in 2022, then dropped by 22.81% to $577.2 million in 2023, then grew by 5.69% to $610.0 million in 2024, then tumbled by 30.29% to $425.2 million in 2025.
  • Its Cash & Current Investments stands at $425.2 million for Q3 2025, versus $487.6 million for Q2 2025 and $494.4 million for Q1 2025.